Comparative Immunogenicity Study of Multiple Doses of Proposed Pegfilgrastim Biosimilar, INTP5 of Intas Pharmaceuticals Ltd., India Against Neulasta of Amgen Inc., USA in Healthy, Adult Human Subjects.

Clinical trial NCT04015232 · COMPLETED

Trial details

NCT number: NCT04015232
Sponsor: Intas Pharmaceuticals, Ltd.
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

Immunogenicity Healthy Volunteers

Start date: 2018-02-26
Primary completion: 2018-06-05
Enrollment: 200

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.